fullstendig cv

Tore J. Gutteberg MD, Ph.D. (dr. med.)

Tore Jarl Gutteberg (290945)

M.D., Ph.D. (Dr med.),

Consultant, Professor II

My present position is Chief Physician /Consultant and Professor in Medical Microbiology at The University Hospital North Norway and University of

Tromsø, Norway. My main interest is antiviral research and medical virology. My hospital duty is acting director of medical microbiology and head of

virology and infection biology section.

A summary of my professional training and experience in the field of medicine.

Educational Council for Foreign Medical Graduates (151-989-1) 19.03.1971

Royal College of Physicians and Surgeons in Ireland, Dublin 16.06.1971

Fully registered Norwegian medical practitioner 16.07.1973

Fully registered practitioner at General Medical Council, Irish Branch, 23.05.1973

Certified as pediatrician 25.10.1978

Certified in medical microbiology (bacteriology, virology, parasitology, mycology, immunization) 25.09.90,

chief physician from that date

Dr. med. (Ph.D.) Lactoferrin as an acute phase reactant. ISBN 82-992382-0-7 May 1991

Professor qualified by an external committee, University of Tromsø, May 1994,

associate professor from 1995, adjusted to professor 2004

October 14, 2011

Tore J. Gutteberg MD, Ph.D. (dr. med.) 2

Summary of education and experience of work

I have practiced as pediatrician and medical microbiologist

Pediatrics Microbiology Clinical Pathology Place From Till

x McMaster; Hamilton. Ontario 1973 1974

x University of Tromsø, Tromsø, Norway 1974 1975

x University Hospital, Tromsø, Norway 1975 1978

x University of Tromsø, Tromsø, Norway 1978 1979

x University Hospital, Tromsø, Norway 1979 1985 1983 Consultant


x National Hospital, Oslo, Norway 1987 1988 Consultant neonatology


x University Hospital, Tromsø, Norway 1989 2011 Consultant Medical Microbiology

x University California, San Diego 1996 1997 Visiting Professor (HIV &CMV at DH & SA Spector Labs)

October 14, 2011


Clinical Microbiology experience

September 24th, 1990 I was a fully licensed clinical microbiologist, covering bacteriology, virology and parasitology. From 1993 I have been engaged in

quality control. 1997 our department did achieve accreditation in microbiology.

For the past 3 -4 years the electronic communication in medical microbiology and towards our users has been part of my job.

Pediatrics

The above table shows more than 10 years of pediatric experience mostly related to neonatology and infectious diseases. This is also reflected in the

list of scientific work.

Teaching

All types of health care professional at undergraduate and postgraduate levels.

Administration

I served as acting director in medical microbiology, University Hospital, Tromsø, 1990-1992 and 1998 till September 2003, from July 2005; and as a

director for periods August 2000-August 2001, November 2002-December 2002, February-March 2003. For 15 years I served as head of medical

virology and infection immunology at our hospital department of microbiology.

From January 1998 till June 2003 I was head of committee for training of specialist in medical microbiology

Initiatives

Pediatric Nursing Education

Mother’s milk bank

Pediatric Infectious Diseases Graduate Education

October 14, 2011


Quality Assurance Clinical Microbiology

Lactoferrin/Lactoferricin/Peptide antimicrobial research

Antiviral Research Group, Tromsø

International

As an international health adviser I have been part of Centre for International Health (SIH) activities the work towards Sri Lanka, Botswana and

Northwest Russia http://uit.no/sih/3747/. Board member of health care faculty, Eastern University, Batticaloa. From 2001 I did participate in the

twinning program between Botswana and Tromsø. Member of the interim board of Norwegian Forum for Global Research http://www.globalhealth.no/

2005-2006. Board member The Norwegian Programme for Development, Research and Education (NUFU) http://siu.no/en/Programme-

overview/NUFU-programme from October 2008. For almost 20 years I have been part of the Hepatitis C North Norway research group (HCV

NN). Some of this work will be a Ph.D. (dr. med.) for Magnhild Gangsøy Krisitiansen. Our intention is to make HCV NN a center of competence for

antiviral treatment. Tromsø Mine Victim Resource Center has been running teaching, treatment and research in Vietnam and Cambodia. I am

consultant in their project on blood safety and we are in the process of publishing our results.

Main objective of my engagement in these bodies is to build network of medical professional teachers in Norway to enhance transfer and exchange of

competence to the third world with emphasis on English speaking Africa. Second objective is to exchange of medical students between Tromsø and

the third world (own list is available). Northern Norway Regional

North Norway Health Authority has given support to from to build collaboration with Malawi, South Africa, University of Tromsø and northern hospitals

on infectious diseases (tuberculosis and other challenges of common interest). Professor Jon Øyvind Odland and I are initiating partners.

http://uit.no/sih/3747/

http://siu.no/en/Programme-overview/NUFU-programme

http://siu.no/en/Programme-overview/NUFU-programme

October 14, 2011


Research

My present research is on antiviral therapy. Prior to that most of my research is in the field of pediatric infectious diseases, infection immunology,

bacteriology and virology.

I have been teaching supervisor for 3 Ph.Ds. (2 antiviral and 1 cardiovascular research) and 2 M.S. and presently two Ph.D. theses, one on hepatitis C

in North Norway and the other on antiviral research.

Most of my published research is listed at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi and a more extensive list in attachment (Scientific work). A

broad line of my research has been related to mother’s milk, lactoferrin and immune response, leading me through innate immunity to virology and

antiviral therapies. Lactoferrin and related peptide research has in Tromsø lead to 11 doctorial theses related to lactoferrin, antiviral, antibacterial and

antitumor activities. The researchers have been part of the establishments of The MARBIO programme (University (UoT) and University Hospital of

Tromsø (UNN),The Norwegian College of Fishery Science (NCFS) is under establishment in Tromsø to explore the ocean for unique bioactivities

(antiviral, antibacterial, antitumor and immunomodulating) in marine organisms) and the bio-company “Lytix”. Since 2006 I am part of an antiviral

research group headed by senior research consultant, Dr.Inge W, Nilsen, Fiskeriforskning, focusing on protease inhibition of HIV-1, HCV and CMV,

Since 1991 I have been member of Hepatitis C North Norway group (initiated by professor Jon Florholmen), presently growing from a health care

project with research to a more focused research project on antiviral therapy of hepatitis C infections. The collaboration with Tromsø Mine Victim

Resource Center research is on hepatitis C and B. related to transfusion safety.

Since January 2006 I have been directing a new project on antiviral therapy based on the application of small RNA molecules (microRNA) and

mapping of mechanisms of conventional antiviral drugs with Dr. Christine Rinaldo (PhD), Eva Bernhoff (Master Virology), Kjersti Sandvik (Bachelor

medical biosciences) and Garth Tylden (MD) , Biswa Nath Sharmaa (Master Virology), Ruomei Li (MD, PhD).

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi

October 14, 2011


Completed theses in the antiviral research field

1. Master of Science (Sivil ingeniør) Håvard Jenssen: Development of cyclic lactoferricin derivatives, determination of affinity to glucosaminoglycans and studies of the antiviral effect against Herpes simplex virus 1 and 2. Tromsø 1999.

2. Dr.scient Jeanette H. Andersen. Ph.D.: Antiviral activity of lactoferrin and lactoferricin against herpesviruses -mode of action. Tromsø 31.10.2003

3. Master of Science (Sivil ingeniør) Eva Bjørkeng. A commissioning trial between commercial anti-HCMV drugs and Lactoferrin evaluated with NASBA. Tromsø 2003.

4. Dr. Håvard Jenssen Ph.D.: Antiviral mode of action of lactoferrin and lactoferricin A model system for design of antiviral peptides with enhanced activity towards Herpes simplex virus. 17. 12.2004.

5. Dr. Dag Seeger Halvorsen Ph.D.: Infection, inflammation and atherosclerosis.Tromsø 9.10.2007

6. Dr.scient Eva Bernhoff: Investigation of antiviral targets in the lifecycle of human polyomavirus BK (BKV)" 3.4.2009

7. Dr. Magnhild Gangsøy Kristiansen Ph.D.: The epidemiological, clinical and immunological spectra of chronic hepatitis C virus infection in Northern Norway. Tromsø June 2010

8. Master of science Biswa Nath Sharma: The effect of fluoroquinolones on BK virus replication in primary human renal proximal tubule epithelial cells. Tromsø June 2010.

Scientific Committees

October 14, 2011


Evaluation of professor competence of Dr. Stig Harthug, University of Bergen (2005)

Ph.D. evaluation and opponent Mabula Joseph Kasubi, University of Bergen, on the thesis “DETECTION AND MOLECULAR

CHARACTERIZATION OF HERPES SIMPLEX VIRUS FROM TANZANIA AND NORWAY” (2006).

Ph.D. evaluation and opponent Maria Ekblad , University of Göteborg, on the thesis

“Anti-herpes simplex virus activities of sulfomannan oligosaccharide PI-88 and disulfated cyclitols ” (2007). Head of Ph.d. committees for Marite Rygh, Kathrine Foyn Bruun, JS Bakken and Vasilis SILAS (2009)

Departmental / Governmental Scientific Committees

Antivral resistance surveillance in Norway (2008-2009) Norwegian government (HOD).

Cervix cancer and human papilloma virus (2009 - ) Norwegian government (HOD).

The Norwegian Programme for Development, Research and Education(Ph.D.) (NUFU) (2008 - )

Scientific supervision

Ph. D. Dr. Hege Kileng:HCV

Ph.D. Master of science Biswa Nath Sharma: Antiviral and polyomavirus

Master Hanne Listau Olsen: Cytogenetic and molekular studies on gene laeverins in pathogenesis of preeclampsia.

SCIENTIFIC WORK (PUBLISHED IN JOURNALS AND BOOKS) BY TORE JARL GUTTEBERG

1. Helle KB, Serck-Hansen G, Søvik O, Gutteberg TJ, Hansen JR, Ose L, Støa KF. Circulating dopamine- beta-hydroxylase and cathecholamines in a pediatric phaeochromocytoma. Clin Exp Pharm Physiol 1976; 3:487-91.

2. Gutteberg TJ, Borud O, Strømme JH. Dopamine-beta-hydroxylase activity in serum following acute myocardial infarction. An evaluation of this parameter for routine use as an index of sympathetic activity. Clin Chim Acta 1976; 69:61-6.

3. Moe PJ, Gutteberg TJ. Høydose methotrexat til barn med maligne sykdommer. Tidsskr Nor Lægeforeningen 1976; 17-18:997-9.

October 14, 2011


4. Mjøs OD, Vik-Mo H, Gutteberg TJ, Strømme JH. Serum dopamine-beta-hydroxylase activity in fasting man. Clin Exp Pharmacol Physiol 1977; 4:323-5.

5. Gutteberg TJ, Noren CE, Moe PJ. Diagnosis and therapeutic studies in idiopathic pulmonary haemosiderosis. Acta Paediatr Scand 1982; 68:913-4.

6. Johannessen A, Gutteberg TJ, Huseby G. Plasma exchange in treatment of severe childhood onset lupus erythematosus. Acta Paediatr Scand 1982; 71:347-50.

7. Melby K, Slørdahl S, Gutteberg TJ, Norbø S. Septicaemia due to yersinia enterocolitica following oral overdose of iron. Brit Med J 1982; 285:467-8.

8. Haneberg B, Gutteberg TJ, Moe PJ, Østerud B, Bjorvatn B, Lehmann EH. Heparin for infants and children with meningococcal septicemia. NIPH Annals 1983; 6:43-7.

9. Gutteberg TJ, Haneberg B, Jørgensen T. The latency of serum acute phase proteins in meningococcal septicemia, with special emphasis on Lactoferrin. Clin Chim Acta 1984; 136:173-8.

10. Gutteberg TJ, Haneberg B, Jørgensen T. Lactoferrin in relation to acute phase proteins in sera from newborn infants with severe infections. Eur J Pediatr 84; 142:37-9.

11. Bjorvatn B, Bjertnes L, Fadnes HO, Flægstad T, Gutteberg TJ, Kristiansen B-E, Pape J, Rekvik OP, Østerud B, Aanderud L. Meningococcal septicemia treated with combined plasmapheresis and leucapheresis or with blood exchange. Brit Med J 1984; 288:439-41.

12. Bolz KP, Skalpe I, Gutteberg TJ. Iohexol and metrizoate in urography in children. Acta Radiol (Diagn) 1984; 251:55-8.

13. Gutteberg TJ, Milman NE, Hansen NE, Cohn J. Serum lactoferrin in children and the correlation to blood leucocytes. Eur Paediatr Haematol Oncol 1984; 1:203-6.

14. Gutteberg TJ, Askvik K, Jørgensen T. Serum lactoferrin and C-reactive protein after preterm rupture of membranes in mother and newborn. Acta Obstet Gynecol Scand 1986; 65:203-205.

15. Dahl LB, Melby K, Gutteberg TJ, Størvold G. Serum levels of ampicillin and gentamicin in neonates of varying gestational age. Eur J Pediatr 1986; 145: 221-3.

16. Gutteberg TJ, Flægstad T, Jørgensen T. C-reactive protein, alpha-1-antitrypsin and immunoglobulin G in cerebrospinal fluid in meningitis. Is lactoferrin of any diagnostic help in bacterial meningitis? Acta Paediatr Scand 1986; 75: 569-72.

17. Bøe B, Størvoll G, Gutteberg TJ. Flavobacterium meningococc meningitt hos nyfødt. Tidsskr Nor Lægeforeningen 1986; 9-10:751-3.

October 14, 2011


18. Milmann N, Gutteberg TJ. Serum beta-2-microglobulin in children. Pediatr Hematol Oncol 1987; 4: 157-167.

19. Gutteberg TJ, Strømme P, Sæbø-Larsen J, Flægstad T.Unilateral vesicoureteral reflux in children: A study on urine osmolality, beta-2-microglobulin and Lactoferrin. Europ J Urol 1987, 13: 390-392.

20. Gutteberg TJ, Slørdal L, Kolmannskog S. Lactoferrin and C-reactive protein in response to cytostatics with emphasis on methotrexate. Pediatr Hematol Oncol 1987; 4: 315-322.

21. Gutteberg TJ. Kan Ibuprofen være et middel ved spesis (Is Ibuprofen a drug in sepsis)? Medica Therapia 1986; 9: 24-27.

22. Gutteberg TJ, Røkke O, Andersen O, Jørgensen T. Lactoferrin as a parameter of septicemia and endotoxemia in pigs. Scand J Inf Dis 1988; 20: 659- 666.

23. Gutteberg TJ. Urinveisinfeksjoner hos barn. Praktiske synspunkter. Tidskr Nor Lægefor 1988; 108: 1895-1897.

24. Gutteberg TJ, Røkke O, Andersen O, Jørgensen T.Early fall of circulating iron and rapid rise of lactoferrin in septicemia: an early defense mechanism. Scand J Infect Dis 1989,21: 709-715.

25. Gutteberg TJ, Østerud B, Volden G, Jørgensen T. The production of Tumor necrosis factor, Tissue Thromboplastin production, Lactoferrin and Cathepsin C release during lipopolysaccharide stimulation. Scand J Clin Lab Invest 1990; 50:421-427

26. Gutteberg TJ, Dalaker K, Vorland L. Early response in neonatal septicemia. The effect of Escherichia coli, group B streptococci and tumor necrosis factor. Acta Pathol Microbiol Immun Scand ( B ) ( APMIS) 1990 ;98: 1027 - 1032

27. Gutteberg TJ, Dalaker, Østerud B, Vorland L. The early septicemic response in the newborns and their mothers due to Escherichia coli, tumor necrosis factor and group B streptococci APMIS 1991; 99: 602-608.

28. Flægstad T, Gutteberg TJ, Kristiansen B-E. Antibodies to meningococcal disease. Scand J Infect Dis 1990; 22: 547 - 553

29. Berdal BP, Scheel O, Gutteberg TJ, Halvorsen D, Hettlevik Ø, Ingebrigtsen T, Mo B, Ånestad G. Chlamydia pneumonia (TWAR) Epidemiology: Experience from Norway. Pages 64 - 72, in: Chlamydial infections, genital tracts, and allied conditions. Ed.: Mårdh P-A, Sikku P. Center for STD Research , Uppsala University Sweden ( ISBN 952- 90 -2826-1) 1991

30. Gutteberg TJ. Lactoferrin as an acute phase reactant. A study focused on infections and the acute phase reaction. Tromsø ( ISBN 82- 992383-0-7 ) 1991

31. Berdal BP, Scheel O, Øgaard AR, Hoel T, Gutteberg TJ, Ånestad G. Spread of subclinical chlamydia infection in a closed community. Scand J Infect Dis 1992; 24: 431 - 436

October 14, 2011


32. Sandven P et al with the Norwegian Yeast Study group. Susceptibilities of Norwegian Candida albicans straina to Fluconazole: emergence of Resistance. Antimicrobiol Agentents Chemother 1993; 37: 2443 -2448.

33. Flægstad T, Kaaresen PI, Stokland T, Gutteberg TJ. Factors associated with fatal outcome in meningococcal disease. Acta Paediatr Scand 1995; 84: 1137 - 1142.

34. Engstad CS, Gutteberg TJ, Osterud B. Modulation of blood cell activation by four commonly used anticoagulants. Thromb Haemost 1997; 77 : 690-696.

35. Vorland LH, Ulvatne H, Andersen J, Haukland HH, Rekdal Ø, Svendsen JS, Gutteberg TJ. Lactoferricin of bovine origin is more active than lactoferricins of human, murine and caprine origin. Scand J Infect Dis 1998; 30: 513-517.

36. Vorland LH, Osbakk SA, Perstølen T, Ulvatne H, Rekdal Ø, Svendsen JS, Gutteberg TJ. Interference of antimicrobial peptide lactoferricin B with various antibiotics against Escherichia coli and Staphylococcus aureus. Scand J Infect Dis 1999; 31: 173-177.

37. Vorland LH, , Ulvatne H, Andersen J, Haukland HH, Rekdal Ø, Svendsen JS, Gutteberg TJ. Antibacterial effects of lactoferricin B. Scand J Infect Dis 1999; 31: 179-184.

38. Viani R, GuttebergTJ, Lathey J, Spector SA. Lactoferrin prevents human immunodeficiency virus type 1 replication in vitro and exhibits synergy when combined with zidovudine. AIDS 1999; 13: 1273-4.

39. Hammer J., Haaheim H. and Gutteberg TJ. Bovine Lactoferrin is more efficient than bovine lactoferricin in inhibiting HSV1/-II replication in vitro in: K-I Shimazaki et al. Lactoferrin: Structure, Function and Applications, 239-243. Amsterdam, Elsevier 2000.

40. Signy Bendiksen, Marjke Van Ghele, Tore Gutteberg, Ole Petter Rekvig, Ugo Moens. A longitudinal study of human cytomegalovirus serology fails to establish an active viral infection in systemic lupus erythematous patients. Lupus 2000; 9: 120-126

41. Jeanette Hammer Andersen, Svein Are Osbakk, Lars Harry Vorland, Terje Traavik , Tore Jarl Gutteberg. Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts. Antiviral Research 2001; 51 (2): 141 – 149

42. Håkon Haaheim, Lars H. Vorland and Tore J. Gutteberg.Laboratory diagnosis of respiratory diseases: PCR versus serology. Nucleosides Nucleotides Nucleic Acids 2001 April-Jul; 20 (4-7): 1255-8.

43. Kristiansen, M Gangsøy, Gutteberg T, Berg LK, Sjursen H, Mortensen L, Florholmen J. Hepatitis C in Northern Part of Norway. Data from an eight years observation program. Tidsskr Nor Laegeforen. 2001 ; 121:446-449.

44. Dag S. Halvorsen, T Børvik, I Njølstad, TJ Gutteberg, LH Vorland, J-B Hansen.. Chlamydia pneumoniae IgA- and IgG antibodies in young survivors of myocardial infarction. A comparison of antibody detection by a microimmunofluorescence test and enzyme immunoassay. J Int Med 2002; 251: 142-147

October 14, 2011


45. Jeanette Hammer Andersen, Håvard Jenssen and Tore Jarl Gutteberg. Lactoferrin and Lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. Antiviral Research 2003; 58: 209-215

46. Håvard Jenssen, Jeanette Hammer Andersen, Lars Uhlin-Hansen , Tore Jarl Gutteberg and Øystein Rekdal. Antiviral activity of lactoferricin analogues is partially related to their affinity for heparan sulphate. Antiviral Res. 2004 ;61:101-109.

47. Jeanette H. Andersen*, Håvard Jenssen, Kjersti Sandvik and Tore J. Gutteberg. The anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparan sulfate at the cell surface . J Med Virol. 2004; 74: 262-71.

48. Anne Husebekk, , Kjell Skaug, Arne Kolstad, Inger Marie S. Dahl,, Tore Gutteberg, Bjørn Skogen. Hepatitis B virus-infected peripheral blood progenitor cell harvests in liquid nitrogen freezer containing non-infectious products. Transfusion (letter) 2004; 44: 942.

49. Håvard Jenssen, Jeanette H. Andersen, Dimitris Mantzilas,Tore J. Gutteberg. A wide range of medium sized, highly cationic, -helical peptides show antiviral activity against herpes Simplex virus. Antiviral Res. 2004;64:119-126.

50. Håvard Jenssen, Tore J. Gutteberg, Tore Lejon. Modelling of anti-HSV activity of lactoferricin analogues using amino acid descriptors. Modeling the anti-HSV activity of small, cationic peptides using amino acid descriptors J Pept Sci. 2005 ;11:97-103.

51. Howard N Hunter, A Ross Demcoe, Håvard Jenssen, Tore Jarl Gutteberg, Hans J Vogel. Human lactoferricin is partially folded and distinct from bovine lactoferricin. Antimicrobial Agents and Chemotherapy. 2005; 49: 3387-3395.

52. Håvard Jenssen, Tore J. Gutteberg,Tore Lejon . Modeling the anti-HSV activity of small, cationic peptides using amino acid descriptors. Journal of Peptide Science 2006; 66 (suppl 1): 48 -56.

53. Håvard Jenssen, Tore J. Gutteberg, Øystein Rekdal ,Tore Lejon. Prediction of Aactivity, Synthesis and Biological Testing of anti-HSV Active Peptides. Chem Biol Drug Des 2006 ;68: 58-66.

54. Dag Seeger Halvorsen, Joachim Karlsen, Ann-Trude W. Notø, Ellisiv B. Mathiesen, Inger Njølstad, Tore Gutteberg, Lars H. Vorland, John-Bjarne Hansen. No detectable Chlamydia pneumoniae DNA and Cytomegalovirus DNA in blood mononuclear cells in subjects with echolucent and echogenic carotid artery plaques. Int J Cardiol. 2007 ;117:388-94.

55. Gutteberg, T. J., C. H. Rinaldo, and H. H. Hirsch. Lactoferrin confidential: ancient actor starring in new role? Transpl. Infect. Dis. 2008;10:77-79.

56. Bernhoff E, Gutteberg TJ, Sandvik K, Hirsch HH and Rinaldo, CH. Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression. American Journal of Transplantation. 2008; 8: 1–10.

October 14, 2011


57. Jenssen H, Sandvik K, Andersen JH, Hancock R EW,. Gutteberg TJ. Inhibition of HSV cell-to-cell spread by lactoferrin and lactoferricin. Antiviral Res. 2008; 79:192-8.

58. Rolv-Ole Lindsetmo, Roar Johnsen, Tor Jac Eide, Tore Gutteberg, Hanne Haukland Husum, Arthur Revhaug. Accuracy of Helicobacter pylori serology in two peptic ulcer populations and in healthy controls.. World J Gastroenterol 2008; 14: 5039-5045.

59. Hvidsten D, Halvorsen DG, Berdal BP, Gutteberg TJ. Chlamydophila pneumoniae diagnostics: importance of methodology in relation to timing of sampling. Clin Microbiol Infect. 2009 Jan;15:42-9.

60. Magnhild Gangsøy Kristiansen1, Bjørn Odvar Eriksen3 , Jan Martin Maltau , Bjørn Holdø1, Tore Jarl Gutteberg , Liisa Mortensen , Maja-Lisa Løchen 3, Jon Florholmen Prevalences of Viremic Hepatitis C and Viremic Hepatitis B in Pregnant Women in Northern Norway. Hepato-Gastroenterology 2009; 56:1141-1145.

61. Ha Sam Ol, Sin Sothy, Yang Van Heng, Bjoern Bjoerkvoll, Hedda Hoel, Stig Larsen, Hans Husum. Prevalence of hepatitis B and hepatitis C virus infections in potential blood donors in rural Cambodia . Southeast Asian Journal of Tropical Medicine and Public Health 2009; 40;5:963-71.

62. Bernhoff E, Tylden GD, Kjerpeseth LJ,Gutteberg TJ, Hirsch HH and Rinaldo CH . Leflunomide inhibits BK virus infection disrupting the nuclear replication architecture in renal tubular epithelial cells. J Virol. . 2010; 84: 2150–2156.

63. Jon Florholmen, Magnhild Gangsøy Kristiansen, Sonja E. Steigen, Sveinung W. Sørbye, Eyvind J. Paulssen, Jan Magnus Kvamme, Zbigniew Konopski , Tore Gutteberg, Rasmus Goll. A rapid chemokine response is associated with a sustained virological response in the treatment of chronic hepatitis C. Clin Microbiol Infect. 2011;17: 204-9.

64. Kristiansen MG, Løchen M-L, Gutteberg TJ, Mortensen L, Eriksen BO, Florholmen J. Total and cause-specific mortality rates in a prospective study of community-acquired hepatitis C virus infection in Northern Norway. J Viral Hepat. 2011; 18: 237 -44.

65. Kristiansen MG, Gutteberg TJ, Mortensen L, Berg LK, Eriksen BO , Goll R, Florholmen J. Clinical outcomes in a prospective study of community-acquired hepatitis C virus infection in Northern Norway. Scand J Gastroenterol. 2010; 45: 746-51.

66. S.W. Sorbye, S. Fismen, T.J. Gutteberg, E.S.Mortensen. HPV mRNA test in women with minor cervical lesions; experience of the University Hospital of North Norway, Journal of Virological Methods 2010 ;169:219-22.

67. S.W. Sorbye, S. Fismen, T.J. Gutteberg, E.S.Mortensen. Triage of women with minor cervical lesions: Data suggesting a "test and treat”

approach for HPV E6/E7 mRNA testing. PLoS ONE 2010 Sep 13;5 (9):e12724.

68. Bjoerkvoll B, Viet L, Ol HS, Lan NT, Sothy S, Hoel H, Gutteberg T, Husebekk A, Larsen S, Husum H. Screening test accuracy among potential blood donors of HBsAg, anti-HBc and anti-HCV to detect hepatitis B and C virus infection in rural Cambodia and Vietnam. Southeast Asian J Trop Med Public Health. 2010 ;41:1127-35.

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bjoerkvoll%20B%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Viet%20L%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ol%20HS%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lan%20NT%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sothy%20S%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hoel%20H%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Gutteberg%20T%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Husebekk%20A%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Larsen%20S%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Husum%20H%22%5BAuthor%5D

October 14, 2011


69. Biswa Nath Sharmaa, Ruomei Li, Eva Bernhoff, Tore Jarl Gutteberga, Christine Hanssen Rinaldo. Fluoroquinolones inhibit human polyomavirus BK (BKV) replication in primary human kidney cells. Antiviral Research 2011 Jul 21. [Epub ahead of print].

70. Sveinung Wergeland Sørbye, Marc Arbyn, Silje Fismen, Tore Gutteberg, Elin Synnøve Mortensen. Triage of women with low-grade cervical lesions - HPV mRNA testing versus repeat cytology. PLoS One. 2011;6(8):e24083. Epub 2011 Aug 30.

71. Sveinung Wergeland Sørbye, Marc Arbyn, Silje Fismen, Tore Jarl Gutteberg, Elin Synnøve Mortensen . HPV E6/E7 mRNA testing is more specific than cytology in postdiagnostic follow-up of women with negative cervical biopsy. PLoS ONE Decision: Accept [PONE-D-11-15426R1 ] 2011.

72. Le Viet, Nguyen Thi Ngoc Lan,, Phung Xuan Ty, Björn Björkvoll, , Hedda Hoel, Tore Gutteberg, , 4, Anne Husebekk, , Stig Larsen, Eystein Skjerve, Hans Husum. Prevalence of Hepatitis B and Hepatitis C Virus Infections in potential blood donors in rural Vietnam. Indian Journal of Medical Research 2011 in press

Scientific work presented as abstracts at poster presentations and oral talks (mostly in international gatherings)

1. Gutteberg TJ. Pulmonal haemosiderosis. Nordisk Paediatr Haematol Club. Upsala 1977.

2. Gutteberg TJ. Akutt fase protein hos nyfødte med sepsis og sannsynlig alvorlig infeksjon. Nor Paediatr Foren. Bergen 1980. 3. Gutteberg TJ. Er bakteriologisk undersøkelse av morsmelk nødvendig ? Nor Paediatr Foren.Bergen 1980. 4. Gutteberg TJ et al. Yersinia enterocolitica sepsis etter jernoverdose. Nor Paediatr Foren . Tromsø 1981.

5. Gutteberg TJ. Latenstid ved akutt fase reaksjon. Nor Paediatr Foren . Oslo 1982.

6. Haneberg B, Gutteberg TJ et al . Heparin i behandling av meningococcsepsis. Symposium NIPH Oslo 1982.

7. Gutteberg TJ. Serum lactoferrin and C-reactive protein in infections. Bicentary Conference of progress in medicine. Dublin 1984.

8. Bjertnes L, Bjorvatn B, Fadnes HO, Flægstad TJ, Pape J, Rekvig OP, Kristiansen B E, Østerud B, Aanderud L. Meningococcal septicemia sucessfully treated with plasmaleucapheresis or bloodexchange.International.J Microcirc 1984 ;3 : 90-1.

October 14, 2011


9. Gutteberg TJ, Østerud B,Volden G. In vitro endotoxin stimulation of granulocytes and monocytes . XXI Nordiska Paediatr Kongress. Oulu 1985.

10. Gutteberg TJ ,Flægstad T. CSF examination of lactoferrin, C- reactive protein, alpha-1- antitrypsin and Ig. XXI Nordiska Paediatr Kongress. Oulu 1985.

11. Stokland T, Flægstad T, Gutteberg TJ. Clinical scoring in meningococcal sepsis. XXI Nordiska Paediatr Kongress. Oulo 1985.

12. Bjertnæs L, Bjorvatn B, Fadnes HO, Flægstad T, Gilbert M, Gutteberg TJ, Kristiansen BE, Pape J, Rekvig OP, Østerud B, Aanderud L. Plasma - leucapheresis or blood exchange in the treatment of meningococcal septicemia. 5 th Intrenational Symposium uber aktuelle Probleme der notfallmedizin und Intenzivtherapie in Munchen. George Thieme Verlag . Stuttgart- New York.1986.

13. Gutteberg TJ. Lactoferrin in relation to blood diseases and cancer in children.Nordisk Forening for pediatrisk hematologi og onkologi ( NOPHO ). IV Annual meeting. COPENHAGEN 1986.

14. Gutteberg T J , Østerud B, Volden G. Endotoxin effect on tissue thromboplastin production and the release of lactoferrin and cathepsin C . The enhancing effect of haemaccel on tissue thromboplastin production. IXth International Congress of Infectious and Parasitic Diseases. Munich 1986.

15. Gutteberg TJ, Flægstad T, Stokland T. Clinical scoring of meningococcal infections. IXth International Congress of Infectious and Parasitic Diseases. Munich 1986.

16. Gutteberg TJ. My experience with lactoferrin in pediatric infections and infectiology. ESPID , Paris 1987.

17. Gutteberg TJ. Lactoferrin in early septicemia. European Society for Pediatric Research, Oslo 1988.

18. Gutteberg TJ, Dalaker K , Vorland L. Early response in neonatal septicemia . The effect of Escherichia coli , Streptococcus agalactiae and tumor necrosis factor. A dose response study on newborn whole blood with regard to lactoferrin generation from granulocytes. Perinatal Year Conference , Trondheim 1989.

19. Berdal Bjørn Petter , Scheel O, Gutteberg TJ. Chlamydia pneumoniae ( TWAR ) pidemiology: Experiences in Norway. The second Scandinavian Chlamydia Meeting, Dundret Gällivarre 1991

20. Kristiansen BE, Flægstad T, Gutteberg TJ, Falk ES, Halstensen A. Antimeningococcal IgG and IgM serum antibodies based on whole bacterium ELISA: Application to meningococcal carriers and patients with meningococcal disease. ESPID, Barcelona 1991

21. Stokland T, Flægstad T, Gutteberg TJ. Children with meningococcal disease - how to select poor prognosis and need for unconventional treatment. ESPID, Barcelona 1991 & 5th ECCMID , Oslo 1991

October 14, 2011


22. Gutteberg TJ , Dalaker K, Vorland LH. Early response in neonatal septicemia and meningitis. Effect of Escherichia coli , Streptococcus agalactiae and tumor necrosis factor on the generation of lactoferrin . ESPID, Barcelona 1991 & 5th ECCMID , Oslo 1991

23. Gutteberg TJ , Dalaker K,Østerud B, Vorland LH. Early response in epticemia in newborns and their mothers. Effect of Escherichia coli , Streptococcus agalactiae and tumor necrosis factor on the generation of lactoferrin , tumor necrosis factor and tissue thromboplastin ( early granulocyte and monocyte activation ). ESPID, Barcelona 1991 & 5th ECCMID , Oslo 1991

24. Gangsøy Kristiansen M, Sjursen H, Gutteberg TJ, Roald B, Florholmen J. Hepatitis C virus in Northern part of Norway. XXVI Nordic Meeting og Gastroenterology. Oslo 1993.

25. Gutteberg TJ. Pediatric aspects in collecting urine samples for microbiological diagnostics. Consensus meeting Norwegian Society for Microbiology. Oslo 1993.

26. Flægstad T, Stokland T, Kaaresen PI, Gutteberg TJ. Children with meningococcal disease : a review of 139 cases. Nordisk pediatrisk forenings barnelegedager. Upsala1994.

27. Gangsøy Kristiansen M, Berg LK, Sjursen H, Gutteberg TJ, Florholmen J. The effect of interferon-alfa 2b on chronic hepatitis C in patients from Northern part of Norway. Nordic Meeting of Gastroenterology , Upsala 1995.

28. Dag S Halvorsen, Tore J Gutteberg. Flowcytometry application in viral research and clinical use, Folkehelsa, Oslo 1995

29. Osbakk SA, Traavik T, Gutteberg TJ, Halvorsen DS, Vorland LH. Antiviral properties of Lactoferricin B, a peptide derived from lactoferrin. Norwegian Society for Virology Meeting , Trondheim 1996.

30. Ulvatne Hilde, Larsen Ø, Gutteberg TJ. A multidisciplinary approach to QA in medical microbiology. Quality in health care. 13th Int. ISQua Conf. Jerusalem 1996.

31. Svein A Osbakk , Tore J Gutteberg , Terje Traavik , Dag S Halvorsen, Lars H Vorland. Lactoferricin B, an antimicrobial peptide derived from Lactoferrin inhibits Human Cytomegalovirus infection in vitro. No 6 11:45-2. First International Congess of Pediatric Infections, Acapulco 1996.

32. Tore J Gutteberg, Svein A. Osbakk, Lars H. Vorland, Nils-Peder Willassen, Terje traavik. Lactoferrin, lactoferricin and heparin inhibit human Cytomegalovirus. No 81. 6th International CMV workshop, Perdido Beach, Alabama 1997.

33. Viani R, GuttebergTJ, , Spector SA. Human and bovine Lactoferrin prevents human immunodeficiency virus type 1 replication in vitro. ICAAC , San Diego, 1998.

October 14, 2011


34. Tore Gutteberg, Dag Seeger Halvorsen, Pia Littauer. Atypical pneumonia and cough challenged the Tromsø way, a diagnostic approach to Bordetella pertussis, Mycoplasma pneumoniae and Chalmydia pneumoniae. Chalmydia pneumoniae Meeting Gardermoen 1998.

35. Pia Littauer Dag Seeger Halvorsen , Lars H Vorland, Tore J Gutteberg. Nyere luftveisdiagnostikk : Bordetella pertussis, Mycoplasma pneumoniae and Chalmydia pneumoniae. Årskonferansen 1998.

36. Dag Seeger Halvorsen , Pia Littauer, Liisa Mortensen, Inger Sofie Samdal Vik, Peter Csango, Einar Aaandahl, Lars H. Vorland,Tore J Gutteberg. MIF IgG av Chlamydia pneumoniae, en prevalens studie. Årskonferansen 1998.

37. Ulvatne H, Gutteberg TJ, Vorland LH. Lactoferricin B shows affinity for phospholipids with a negative charge. ASM 1999.

38. Konopski Z, Gangsoy Kristiansen M, Eriksson Steigen S, Gutteberg TJ, Florholmen J. Chemokine profile and histological

changes in liver during treatment of hepatitis C with interferon-. AGA 1999.

39. Florholmen J, Gangsoy Kristiansen M, Eriksson Steigen S, Gutteberg TJ,Konopski Z. Chemokine profile during treatment with interferon-alpha in patients with chronic hepatitis C. Hepatolology 1999: 4: 1720.

40. Jeanette Hammer, Håkon Haaheim, Tore J Gutteberg. Lactoferrins inhibit Herpes simplex virus in vitro. NBS, Tromsø 1999.

41. Håkon Haahem , Jeanette Hammer, Tore J Gutteberg. Applied science –a brief evaluation of Hexaplex, a biogenetic tool for the identification of common respiratory viruses. NBS, Tromsø 1999.

42. Jeanette Hammer, Håkon Haaheim, Tore J Gutteberg. Lactoferrin shows better inhibition than lactoferricin of Herpes simplex virus in vitro. IV International Lactoferrin Conference, Sapporo 1999.

43. Jeanette Hammer Andersen, Tore J Gutteberg. Lactoferrin, lactoferricin reduce the presence of HSV 1 and HSV 2 DNA in fibroblasts. 24th International Herpes work shop, Boston 1999.

44. Tone Skarpaas, Pål Jenum, Tore J Gutteberg. Evaluation of 12 kits for detection of antibodies to Borrelia burgdorferi sensu lato. VII Int Conf Lyme Borreliosis and other emerging tick.borne diseases. Munich 1999.

43. Gangsoy Kristiansen M, Husebekk A, Mollnes TE, Gutteberg TJ, Halvorsen D S, Mortensen L, Florholmen J.

Prevalence of Hepatitis C infection in blood donors in Northern Norway. Nordic Meeting of Gastroenterology. Tromsø 1999.

44 Andersen Hammer J, Gutteberg TJ. Lactoferrin and lactoferricin inhibit Herpes simplex virus 1 and 2 antigen expression in clinical isolates

of Herpes simplex virus 1 and 2. ICAAC. San Francisco 1999.

October 14, 2011


45 Andersen Hammer J, Gutteberg TJ. Lactoferrin and lactoferricin inhibit HSV and HCMV infection in human fibroblasts. Norwegian Society for

Virology. Bergen 1999.

46 Anne-Kristin Natland, Tore J. Gutteberg, Håkon Haaheim. A methodological comparison; laboratory diagnosis of respiratory diseases using PCR versus serological assay. Vancouver 2000.

47 Håkon Haaheim, Lars Vorland, Tore J. Gutteberg. Laboratory diagnosis of respiratory disease; PCR versus serology. San Francisco 2000.

48 Håvard Jenssen ; Øystein Rekdal, Tore J. Gutteberg. Development of cyclic lactoferricin B analogues, establishment of their affinity towards glucosaminoglycans and study of the antiviral activity against Herpes simplex 1 and 2. Malta 2000.

49 Håvard Jenssen ; Øystein Rekdal, Tore J. Gutteberg. Strategies for development of lactoferricin B analogues with increased antiviral activity against HSV 1&2. V International Lactoferrin Conference, Calgary 2001.

50 Jeanette Hammer Andersen , Håvard Jenssen, Kenneth Thompson, Tore J. Gutteberg. Antiviral activity of lactoferricin against clinical isolates of HSV-1 and 2. Poster 62. 15th ICAR, Prague 2002.

51 Jeanette Hammer Andersen, Håvard Jenssen, Tore J. Gutteberg. Lactoferrin and lactoferricin inhibits HSV-1 and 2 infection and exhibit synergy with acyclovir. Norwegian Society for Virology, Tromsø, 2002

52 Jeanette Hammer Andersen, Håvard Jenssen, Tore J Gutteberg. Lactoferricin inhibits the entry of HSV-1. 27th International Herpes work shop, Cairns 2002. Jeanette Hammer Andersen, Håvard Jenssen, Tore J Gutteberg. Lactoferricin inhibits the entry of HSV-1. 27th International Herpes work shop, Cairns 2002.

53 Håvard Jenssen , Jeanette Hammer Andersen , Tore J Gutteberg. Does antiviral activity of cyclic lactoferricin H analogues against Herpes simplex 1 and 2 depend on heparan sulphate affinity? 27th International Herpes work shop, Cairns 2002.

October 14, 2011


54 Jeanette Hammer Andersen, Kjersti Sandvik, Håvard Jenssen, Tore J Gutteberg. Antiviral activity of lactoferrin and lactoferricin against Herpes simplex virus. Norwegian Biochemistry Society, Geilo 2003.

55 Jeanette Hammer Andersen, Håvard Jenssen, Tore Jarl Gutteberg. Lactoferrin and lactoferricin are important co-factors in treatment of HIV-1, herpes virus 1, 2, and 5. Sixth international conference on lactoferrin: structure, function, applications. Capri 2003.

56 Håvard Jenssen, Jeanette Hammer Andersen and Tore Jarl Gutteberg . A wide range of medium sized, highly cationic, alpha-helical peptides show antiviral activity against HSV. 28th International Herpes work shop, Madison 2003.

57 K. Sandvik, J.H. Andersen, H. Jenssen, T.H. Laupstad and T.J. Gutteberg .Localization of Lactoferrin and Lactoferricin in Chinese Hamster Ovary cells and how this is related to their antiviral activity against HSV infection.28th International Herpes work shop, Madison 2003.

58 Håvard Jenssen, Kjersti Sandvik, Thomas Laupstad, Tore Jarl Gutteberg. Cellular localization and heparan sulfate affinity of apo-lactoferrin and iron saturated lactoferrin in respect to their antiviral activity against HSV. 29th International Herpes work shop, Reno 2004.

59 Håvard Jenssen, Tore Jarl Gutteberg, Tore Leijon. Modeling of anti-HSV activity of lactoferricin analogues using amino acid descriptors. The 15th European Symposium on Quantitative Structure-Activity Relationships, Istanbul 2004.

60 Jenssen, H., Gutteberg, T.J., Rekdal, Ø., Lejon T.S. Prediction of activity, synthesis and biological testing of anti-HSV active peptides. Poster. Organisk Kjemisk Vintermøte 2005; 13.-16.01.2005.

61 Haaheim H, Nygård M, . Gutteberg TJ, Simonsen GS1, Nygård JF. HPV E6/E7 mRNA detection and concurrent Pap smear cytology in a population of 19,152 Norwegian women aged 13 to 87 years. 22nd International Papillomavirus Conference and Clinical Workshop in Vancouver 2005.

62 Kristiansen MG, Maltau JM, Holdø B, Gutteberg TJ, Mortensen L, Løchen M-L, Eriksen BO, Florholmen J. M. Prevalence of Hepatitis C and B in Pregnant Women in North Health Region of Norway. UEGW. Copenhagen 2005.

63 Håvard Jenssen, Tore Jarl Gutteberg. LACTOFERRIN AND LACTOFERRICIN INHIBIT HERPES SIMPLEX VIRUS CELL-TO-CELL SPREAD. Seventh international conference on lactoferrin: structure, function, applications. Hawaii 2005.

64 Håvard Jenssen, Tore Jarl Gutteberg, Robert E. Hancock . LACTOFERRIN AND LACTOFERRICIN INHIBIT HERPES SIMPLEX VIRUS CELL-TO-CELL SPREAD AND POSSES CHEMOTACTIC FUNCTION. 31th International Herpes work shop, Seattle 2006.

65 Eva Bernhoff, Tore Gutteberg, Kjersti Sandvik, Hans H Hirsch and Christine H Rinaldo. Effect of Cidofovir on Polyomavirus BK Replication. Third European Congress of Virology 2007

October 14, 2011


66 Eva Bernhoff, Tore Gutteberg, Kjersti Sandvik, Hans H Hirsch and Christine H Rinaldo. Time-dependent Effect of Cidofovir on Polyomavirus BK Replication and Kidney Cell Viability. I V I N T E R N AT I O N A L C O N F E R E N C E ON Polyomaviruses and Human Diseases 2007.

67 Eva Bernhoff, Tore Gutteberg, Kjersti Sandvik, Hans H Hirsch and Christine H Rinaldo . EFFEKT AV CIDOFOVIR PÅ POLYOMAVIRUS BK REPLIKASJON.. FHI,Oslo 2007.

68 Christine H Rinaldo, Eva Bernhoff, Garth Tylden, Kjersti Sandvik, Hans H Hirsch and Tore J Gutteberg. Time-dependent Effect of Cidofovir and Leflunomide on Polyomavirus BK Replication and Kidney Cell Viability. American Transplant Congress Toronto 2008.

69 Bernhoff, E, Tylden,GD, Gutteberg TJ, Sandvik K, and Rinaldo, CH. Effects of leflunomide on Polyomavirus BK (BKV) Replication and Kidney Cell Viability. ESCV , Saariselkä 2008.

70 Bernhoff E, Gutteberg TJ, Sandvik K, Hans H Hirsch and Rinaldo, CH. Time-dependent Effect of Cidofovir on Polyomavirus BK (BKV) Replication and Kidney Cell Viability. ESCV Saariselkä 2008.

71 Bernhoff, E, Tylden,GD, Gutteberg TJ2, Sandvik K, and Rinaldo, CH. Effects of leflunomide on Polyomavirus BK (BKV) Replication and

Kidney Cell Viability. Norsk virologisk forening . Kristiansand 2008.

72 Kristiansen MG, Løchen M-L, Gutteberg T, Falk E, Mortensen L, Florholmen J, Eriksen BO. Prevalence of Hepatitis C Virus Infection in Patients with Sporadic Porphyria Cutanea Tarda, Membranoproliferative or Membranous Glomerulonephritis in Northern Norway. Helsinki 2008.

73 Håvard Beck, Stefan Bringsli, Magnhild Gangsøy Kristiansen, Gutteberg Tore, Rasmus Goll, Jon Florholmen. A rapid 24 hours chemokine response and a substantial decline in virus load are associated with a sustained virological response in treatment of chronic hepatitis C infection. UEGW. Vienna, Austria 2008.

74 Sørbye SW, Fismen S, Gutteberg T and Mortensen ES. THE USE OF AN RNA-BASED HPV-TEST IN CERVIX CYTOLOGICAL SCREENING - Experience from the University Hospital of Northern Norway. EUROGIN, Nice – France 2008

October 14, 2011


75 Bernhoff E,Tylden G, Kjerpeseth L,J, Gutteberg TJ, Hirsch HH, Rinaldo C. Leflunomaide inhibits BK virus replication but simultaneously compromises renal tubular epithelial cell proliferation. ESCV, Instabul 2009.

76 Rinaldo CH, Naess H, Øksendal N, Halvorsen H, Glad S, Lindal S, Storstein, Gutteberg TG, Scheie D, Mørk S, Hirsch HH, Myhr K. Two cases of PML in Norwegian Patients Without Known Risk Factors of Immunodeficiency. Third meeting on HIV infection and the central nervous system. Stresa, Italy 2009.

77 E. Bernhoff, B.S. Nath, T.J. Gutteberg, C.H. Rinaldo. ANTIVIRAL EFFECT OF CIPROFLOXACIN AND OFLOXACIN ON HUMAN POLYOMAVIRUS BK (BKV) REPLICATION IN PRIMARY HUMAN KIDNEY CELLS ECV , Lake Como,Italy, 2010

78 Kjelsberg,K, Larsen G, Hansen CR, GuttebergTJ. Er HIV BLOT moden fro utskifting? INNO-LIA –en billigere og sikrere vei til rett HIV-diagnose. Bioingeniørkongressen, Oslo 2010.

79 Kileng H, Gutteberg TJ, Kristiansen MG, Moen OS, Paulssen EJ, Mortensen L and Florholmen J. Outcomes of hepatitis C virus diagnostics in Northern Norway 2005-2008. 5th Conference on Global Health and Vaccination Research, Tromsø, 2010.

80 Kileng H , Kristiansen MG, Moen OS, Paulssen E,Gutteberg T , Mortensen L, and Florholmen J. The epidemic of diagnosed hepatitis C in Northern Norway . . 5th Conference on Global Health and Vaccination Research, Tromsø, 2010.

81 Sørbye SW, Fismen S, Gutteberg T and Mortensen ES. Study of HPV mRNA testing in HPV triage. 26’th International Papillomavirus Conference & Clinical and Public Health Workshops • Montreal• July 3-8, 2010.

82 Sørbye SW, Fismen S, Gutteberg T and Mortensen ES. HPV mRNA TEST HOS KVINNER MED MINDRE CYTOLOGISKE FORANDRINGER.

Årsmøtet Norsk Gynekologisk Forening i Arendal, 2010.

83 Sharma BN, Bernhoff E, Gutteberg TJ, Rinaldo CH. ANTIVIRAL EFFECT OF CIPROFLOXACIN AND OFLOXACIN ON HUMAN POLYOMAVIRUS BK (BKV) REPLICATION IN PRIMARY HUMAN KIDNEY CELLS. Antiviral Congress. Amsterdam 2010.

84 Sørbye SW, Fismen S, Gutteberg T and Mortensen ES. Follow-up of women with negative biopsy- HPV E6/E7 mRNA testing versus cytology. Norsk patologisk forening. 2011.

85 Mortensen ES

1,3 Sørbye SW

1, Fismen S

1 og Gutteberg T

2,3 Undersøkelse av kvinner med negativ biopsi etter cytologisk HSIL Norsk forening

for klinisk cytologi. 2011.

86 Sørbye SW, Fismen S, Gutteberg T and Mortensen ES .TRIAGE OF WOMEN WITH LSIL – HPV E6/E7 mRNA TESTING VERSUS REPEAT CYTOLOGY Norsk forening for klinisk cytologi. 2011.

October 14, 2011


87 Sorbye SW, Fismen S, Gutteberg T and Mortensen ES.HPV MRNA testing - long term follow up of 20,000 women in Norway. EUROGIN .

Lisbon, Portugal, May 8 – 11, 2011

88 Sorbye SW, Fismen S, Gutteberg T, Mortensen ES and Skjeldestad FE. HPV mRNA TEST IN PRIMARY SCREENING OF WOMEN 20-34 YEARS. . International Papillomavirus Conference 17-22 September 2011, Berlin, Germany.

Tromsø 2011

Tore Jarl Gutteberg

fullstendig cv

Documents